Janice Hitchcock, Ph.D., has extensive experience in regulatory affairs and drug development, with over 30 years in the pharmaceutical industry. Hitchcock joined Acumen in 2018 to lead regulatory strategy for ACU193. She was previously at Eli Lilly and Company for 17 years, where she was regulatory affairs director responsible for Alzheimer’s disease drug development programs and supported several public-private collaborations in Alzheimer’s disease. Hitchcock received Lilly Research President’s Awards for establishing regulatory recommendations for biologics development and for engaging external stakeholders on Alzheimer’s disease regulatory policy. She was also named one of Lilly’s top 100 Innovators for her contributions to the first clinical trial in preclinical Alzheimer’s disease. She received her doctorate in psychology from Yale University, and headed a behavioral pharmacology laboratory for 10 years at Hoechst Marion Roussel/Aventis. Hitchcock is also co-author of several patents.